It’s been a complicated year for tech firms outside those “Magnificent Seven” names that have, to some degree, outgrown a simple “tech” distinction. High interest rates have taken a toll on tech firms. That includes biotech firms that rely on borrowing in early stages before they can have patents approved. Despite that, however, at least [...] The post Biotech ETF SBIO Sees Buy Signal Amid Hot Returns appeared first on ETF Trends .